GlassScriptPhysician profile
Suzi Kochar
NPI 1528387834
$11,214.07
in general payments reported to CMS, 2019-2025
50 companies · $1,609 in 2025
The $1,609 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,463 · 2020: $1,117 · 2021: $1,420 · 2022: $2,431 · 2023: $1,187 · 2024: $1,987 · 2025: $1,609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,910 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $813 · Education: $59.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,910.48 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $813.00 |
| Education | $59.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $2,319.75 | 2019-2025 | Korlym |
| Novo Nordisk INC | $2,122.80 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $792.48 | 2019-2022 | |
| Abbott Laboratories | $660.48 | 2019-2025 | Freestyle Libre 3 |
| Cequr Corporation | $485.44 | 2023-2025 | Cequr Simplicity |
| Abbvie INC. | $454.01 | 2019-2025 | |
| Senseonics, Incorporated | $400.00 | 2024 | Eversense |
| Lilly USA, LLC | $342.40 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Xeris Pharmaceuticals, INC. | $335.73 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Medtronic, INC. | $286.32 | 2021-2025 | Minimed 780g, Minimed 770g |
| Mannkind Corporation | $232.72 | 2019-2024 | Afrezza |
| Insulet Corporation | $225.86 | 2019-2024 | Omnipod |
| Amgen INC. | $212.22 | 2019-2025 | Tepezza, Evenity, Prolia |
| Sanofi-Aventis U.S. LLC | $206.06 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $190.45 | 2022-2024 |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $188.80 | 2019-2023 | Jardiance |
| Neurocrine Biosciences, INC. | $147.14 | 2024-2025 | |
| Ascendis Pharma Endocrinology INC | $145.20 | 2023-2025 | Yorvipath |
| Tandem Diabetes Care, INC. | $135.91 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $120.88 | 2021-2025 | Dexcom G6 Transmitter |
| Recordati_rare_diseases_inc. | $111.95 | 2021-2025 | Isturisa |
| Boston Scientific Corporation | $91.92 | 2021 | |
| Amneal Pharmaceuticals LLC | $86.88 | 2020-2025 | Unithroid |
| Shire North American Group INC | $70.17 | 2019 | |
| Radius Health, INC. | $62.50 | 2019-2023 | |
| Averitas Pharma INC. | $54.44 | 2025 | Qutenza |
| Merck Sharp & Dohme LLC | $50.54 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $49.62 | 2023-2024 | Strensiq |
| Beta Bionics, INC. | $49.19 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Verity Pharmaceuticals INC. | $46.07 | 2024-2025 | Tlando |
| Horizon Therapeutics Plc | $41.06 | 2020-2023 | Tepezza |
| Rgh Enterprises LLC | $40.00 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.83 | 2020 | |
| Acella Pharmaceuticals, LLC | $36.17 | 2024-2025 | NP Thyroid 60 |
| Esperion Therapeutics, INC. | $34.51 | 2021-2025 | Nexletol |
| Medtronic Minimed, INC. | $33.83 | 2019 | |
| Astellas Pharma US INC | $31.54 | 2024-2025 | Veozah |
| Eusa Pharma (US) LLC | $28.98 | 2022 | |
| Nevro Corp. | $28.87 | 2023-2024 | Senza |
| Rhythm Pharmaceuticals, INC. | $27.96 | 2025 | Imcivree |
| Strongbridge US INC. | $27.16 | 2020 | |
| Madrigal Pharmaceuticals | $26.02 | 2025 | Rezdiffra |
| Amryt Pharma Holdings LTD | $25.41 | 2023 | Myalept |
| Alvogen INC | $20.00 | 2023 | Teriparatide |
| Ascensia Diabetes Care US INC. | $17.89 | 2023 | |
| Pfizer INC. | $17.49 | 2025 | |
| Currax Pharmaceuticals LLC | $17.33 | 2025 | Contrave |
| Tolmar, INC. | $15.37 | 2024 | |
| Antares Pharma, INC. | $14.84 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.88 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzi Kochar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.